Person
Independent Continuant
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing Oral SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis.
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety.
Agent
A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
Oral CLADribine in patients that Change from firstline Disease Modifying Treatments for Multiple Sclerosis: a pROspective effectivenesS and Safety study (CLAD CROSS)
Pediatric Neuromyelitis Optica Spectrum Disorder (NMOSD) Study
A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE SAFETY AND EFFICACY OF OCRELIZUMAB IN CHILDREN AND ADOLESCENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
RDF description of TOMASSINI VALENTINA - http://irises.unich.it/resource/person/240239
STUDIO DI FASE IIIB, MULTICENTRICO, RANDOMIZZATO, IN DOPPIO CIECO E CONTROLLATO VOLTO A VALUTARE L’EFFICACIA, LA SICUREZZA E LA FARMACOCINETICA DI UNA DOSE DI OCRELIZUMAB PIÙ ELEVATA IN ADULTI CON SCLEROSI MULTIPLA PRIMARIAMENTE RECIDIVANTE